ERBB2 and neoplasm: In this study we investigated new targeted treatment options for HER2-negative, PI3KCA-mutated mGAC using the circulating tumour cell line UWG02CTC and the HER2-negative, PI3KCA-mutated adenocarcinoma cell line AGS as a non-CTC but mGAC comparator cell line.